Celgene gets FDA breakthrough therapy designation for Pomalyst to treat Kaposi sarcoma

The designation has been granted for Pomalyst to treat patients with HIV-positive Kaposi sarcoma who have previously received systemic chemotherapy, in addition to patients with HIV‐negative Kaposi’s sarcoma.